

31<sup>st</sup> July, 2021

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051.  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, (“Listing Regulations”)**

---

We refer to our disclosure, dated 31<sup>st</sup> March 2021, under Regulation 30 of the Listing Regulations informing inter alia that DigiHealth Technologies LLP (“Digihealth”) [(the wholly owned entity of our investee entity, ABCD Technologies LLP wherein our company holds presently 6.45% share of profit / loss and voting rights)] had acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited (“AWACS”) and the acquisition was completed on 30<sup>th</sup> March 2021, through a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited (“Trikaal”). Further, it was informed that Digihealth had agreed to acquire the remaining 33.98% ownership interest in AWACS and had entered into legally binding agreements for such acquisition of the remaining stake.

Further to the above and in terms of Regulation 30 of Listing Regulations read with SEBI Circular, we wish to inform you that Digihealth has now completed the acquisition of an additional 65.91% of shareholding in Trikaal by purchase of shares from certain shareholders of Trikaal at a cash consideration of ₹ 24,71,52,845 (Indian Rupees Twenty-Four Crores Seventy One Lakh Fifty Two Thousand Eight Hundred and Forty Five only) and thereby indirectly, Digihealth has completed the acquisition of a total of 98.97 % of shareholding in AWACS.

In furtherance, we would also wish to inform you that the acquisition of remaining shareholding of 2.05% in Trikaal is envisaged to be completed over the course of next few months subject to certain terms and conditions.



**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Kindly take note on above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

